| dc.description.abstract | Breast cancer is the most common cancer among women in my country, with a peak incidence between the ages of 45 and 69 and the leading cause of cancer death in women worldwide. Among various types of breast cancer, triple-negative breast cancer has high drug resistance and a high recurrence rate during treatment, which in turn leads to high mortality, and is prone to early metastasis clinically, and there are few treatment options. At present, the drug treatment is still mainly chemotherapy. In recent years, hydrogels have been widely used for tumor drug delivery. A hydrogel drug carrier can cause less side effects than systemic chemotherapy and can achieve sustained delivery of a drug at tumor sites. We have developed an injectable hydrogel which prepared from divalent cations (Ca2+) and sodium alginate. This hydrogel contains camptothecin (CPT) nanoparticles and indocyanine green (ICG) perfluorocarbon nanoemulsions (HGCNIPNs) and can provide photo/chemotherapy at the same time. Through DLS analysis, the size of CPTNPs and ICGNPs are 483.23±113.0 nm and 219.76±13.11 nm, respectively, the potentials are 28.51±3.35 mV and -33.27±4.90 mV, and both of nanoparticles have high encapsulation rate, which are higher than 92%. In comparison to freely dissolved ICG, the ICG in the hydrogel enhances thermal stability and provides a comparable hyperthermia effect, and the production of singlet oxygen under near-infrared (NIR; 808 nm, 6 W/cm2) irradiation is significantly increased. In addition, in vitro cell experiments showed that HGCNIPNs (ICG=160 μM; CPT=300 μM) are more cytotoxic than the same concentration of Free CPT and CPTNPs groups, with significant differences in survival rates of 23.57%, 75.80% and 68.12%, respectively. The results of in vivo animal studies showed that HGCNIPNs are most effective in tumor suppression at ICG of 160 μM and CPT of 300 μM, and don′t cause serious damage to vital organs such as heart, liver, spleen, lung and kidney. This study confirms that HGCNIPNs have great potential in the application of photothermal and photodynamic therapy, through phototherapy to inhibit cancer cells first, and then use the drug to slowly release from the carrier to achieve simultaneous photo/chemotherapy, reducing the dosage and side effects. Alginate hydrogel can be treated by simply mixing in water and noninvasive injection. It has considerable advantages in synthesis, storage, drug delivery, and clinical applications, and HGCNIPNs are expected to have further development in the future. | en_US |